Horia Pribiag
Scientist, Stanley Center for Psychiatric Research Broad Institute of MIT & Harvard
Dr. Pribiag is a Scientist at the Broad Institute of MIT and Harvard, leading neurodegeneration and neuropsychiatric drug discovery projects. He has extensive experience with in vitro and in vivo pharmacology, microglial biology, transcriptomic analyses, neural circuit biology, and preclinical models of neurodegeneration and neuropsychiatric disorders. Dr. Pribiag manages cross-functional teams and collaborates with computational biologists and CROs to advance target validation and drug discovery. He completed postdoctoral training at UC San Diego and holds a PhD in Neuroscience from McGill University.
Seminars
Wednesday 15th April 2026
Targeting the Complement Pathway to Modulate Neuroinflammation in Neurodegenerative Disorders
9:30 am
- Complement activation is a key aspect of the neuroimmunological response to neurodegenerative disorders
- Glial cell reactivity is modulated by multiple complement system components that could be leveraged for therapeutic benefit
- Brain-penetrant complement therapeutics: efforts to develop a small molecule inhibitor of C3aR to overcome the limitations of antibody-based complement inhibitors
- Evaluating pharmacodynamic biomarkers of C3aR inhibition in preclinical models of neurodegeneration
